Literature DB >> 8384914

Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: prognostic value and therapeutic benefit.

W F Hendry1, R P A'Hern, J W Hetherington, M J Peckham, D P Dearnaley, A Horwich.   

Abstract

Between 1976 and 1990, 231 patients had excision of para-aortic lymph node masses remaining after chemotherapy for metastatic non-seminomatous germ cell tumours. The overall 5-year survival rate was 80%. Multivariate analysis of survival after surgery was performed and the following were found to be independent prognostic variables: completeness of surgical excision, pathology of excised mass, timing of surgery after chemotherapy (elective versus salvage) and year of treatment (before or after 1984). Para-aortic lymphadenectomy provided both therapeutic benefit and histological information of prognostic value in planning future treatment and follow-up. Size of mass and serum markers at the time of surgery were of no additional prognostic value once completeness of excision and pathology were taken into account. We therefore recommend that all residual masses should be removed soon after completion of chemotherapy.

Entities:  

Mesh:

Year:  1993        PMID: 8384914     DOI: 10.1111/j.1464-410x.1993.tb15920.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  13 in total

1.  Disorders of ejaculation.

Authors:  W F Hendry
Journal:  Ann R Coll Surg Engl       Date:  1999-09       Impact factor: 1.891

2.  Canadian consensus guidelines for the management of testicular germ cell cancer.

Authors:  Lori Wood; Christian Kollmannsberger; Michael Jewett; Peter Chung; Sebastian Hotte; Martin O'Malley; Joan Sweet; Lynn Anson-Cartwright; Eric Winquist; Scott North; Scott Tyldesley; Jeremy Sturgeon; Mary Gospodarowicz; Roanne Segal; Tina Cheng; Peter Venner; Malcolm Moore; Peter Albers; Robert Huddart; Craig Nichols; Padraig Warde
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

3.  Iatrogenic damage to male reproductive function.

Authors:  W F Hendry
Journal:  J R Soc Med       Date:  1995-10       Impact factor: 5.344

Review 4.  Diagnosis and treatment of patients with testicular germ cell cancer.

Authors:  J T Hartmann; L Kanz; C Bokemeyer
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

5.  Post-chemotherapy robot-assisted retroperitoneal lymph node dissection in non-seminomatous germ cell tumor of testis: Feasibility and outcomes of initial cases.

Authors:  Ekrem İslamoğlu; Çağatay Özsoy; Hakan Anıl; Yasin Aktaş; Mutlu Ateş; Murat Savaş
Journal:  Turk J Urol       Date:  2018-12-20

6.  Results of salvage retroperitoneal lymphadenectomy (RLA) in the treatment of patients with nonseminomatous germ cell tumours remaining marker positive after inductive chemotherapy.

Authors:  L Kisbenedek; I Bodrogi; P Szeldeli; M Baki; P Tenke; J Horti
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

7.  Imaging of testicular germ cell tumours.

Authors:  P U Dalal; S A Sohaib; R Huddart
Journal:  Cancer Imaging       Date:  2006-09-07       Impact factor: 3.909

8.  Salvage therapy of germ cell tumours.

Authors:  A Horwich
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

9.  Resection of residual retroperitoneal masses in testicular cancer: evaluation and improvement of selection criteria. The ReHiT study group. Re-analysis of histology in testicular cancer.

Authors:  E W Steyerberg; H J Keizer; S D Fosså; D T Sleijfer; D F Bajorin; J P Donohue; J D Habbema
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

10.  Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminomatous germ cell tumours.

Authors:  A Gerl; C Clemm; N Schmeller; H Dienemann; M Weiss; M Kriegmair; U Löhrs; W Wilmanns
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.